AbbVie Acquires ImmunoGen for $10.1 Billion, Expanding Solid Tumor Portfolio

AbbVie Acquires ImmunoGen for $10.1 Billion, Expanding Solid Tumor Portfolio

by | Nov 30, 2023 12:28 pm | Biotechnology

AbbVie Inc. and ImmunoGen, Inc. announced on November 30 a definitive agreement under which AbbVie will acquire ImmunoGen, a publicly traded biotechnology company focused on the development of antibody-drug conjugate (ADC) technology to treat cancer.  Under the terms of the transaction, AbbVie will acquire all outstanding shares of ImmunoGen for $31.26 per share in cash. The transaction values ImmunoGen at a total equity value of approximately $10.1 billion.  ImmunoGen’s flagship cancer therapy ELAHERE® (mirvetuximab soravtansine-gynx) is approved for the treatment of platinum-resistant ovarian cancer. According to its 2022 financial report, ImmunoGen had total revenues of... Read More »
BV Investment Partners Announces Investment in Hardenbergh Group

BV Investment Partners Announces Investment in Hardenbergh Group

by | Aug 16, 2023 2:20 pm | Healthcare Staffing, Other Services, Private Equity

Private equity firm BV Investment Partners has announced a growth-oriented investment in Hardenbergh Group, a provider of non-clinical professional staffing, consulting, physician peer review and outsourced solutions to healthcare organizations nationwide. Founded in 1991 by Mary Hardenbergh and based in Livonia, Michigan, Hardenbergh Group offers services in consulting and the interim staffing of medical services professionals and other non-clinical roles essential to patient safety, quality of care and other governance, risk and compliance requirements of leading healthcare organizations. BV Investment Partners is one of the oldest and most experienced sector-focused private equity firms... Read More »

Medtronic Swoons over HeartWare

by | Jun 29, 2016 8:00 am | Medical Devices

Medtronic plc (NYSE: MDT) kept up its busy acquisition pace, notching its fifth deal in 2016. The target is HeartWare International (NASDAQ: HTWR), developer and maker of miniaturized implantable heart pumps or ventricular assist devices (VAD) for the treatment of advanced heart failure. Its lead product is the HVAD® System, featuring the world’s smallest full-support ventricular assist device. Medtronic will pay $58.00 per share in cash for all outstanding common stock in HeartWare, for a transaction value of $1.1 billion. This acquisition will expand Medtronic’s portfolio of diagnostic tools, therapies and services for patients suffering from heart failure. The transaction is... Read More »